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Abstract
Nonalcoholic fatty liver disease (NAFLD) is an emerging risk factor for heart failure (HF).
Although some progress has been made in improving survival among patients admitted for
HF, the rates of hospital readmissions and the related costs continue to rise dramatically.
We sought to examine whether NAFLD and its severity (diagnosed at hospital admission)
was independently associated with a higher risk of 1-year all-cause and cardiac re-hospi-
talization in patients admitted for acute HF. We studied 212 elderly patients who were con-
secutively admitted with acute HF to the Hospital of Negrar (Verona) over a 1-year period.
Diagnosis of NAFLD was based on ultrasonography, whereas the severity of advanced
NAFLD fibrosis was based on the fibrosis (FIB)-4 score and other non-invasive fibrosis
scores. Patients with acute myocardial infarction, severe valvular heart diseases, end-
stage renal disease, cancer, known liver diseases or decompensated cirrhosis were
excluded. Cox regression was used to estimate hazard ratios (HR) for the associations
between NAFLD and the outcome(s) of interest. The cumulative rate of 1-year all-cause
re-hospitalizations was 46.7% (n = 99, mainly due to cardiac causes). Patients with
NAFLD (n = 109; 51.4%) had remarkably higher 1-year all-cause and cardiac re-hospitali-
zation rates compared with their counterparts without NAFLD. Both event rates were par-
ticularly increased in those with advanced NAFLD fibrosis. NAFLD was associated with a
5-fold increased risk of 1-year all-cause re-hospitalization (adjusted-hazard ratio 5.05,
95% confidence intervals 2.78–9.10, p<0.0001) after adjustment for established risk fac-
tors and potential confounders. Similar results were found for 1-year cardiac re-hospitaliza-
tion (adjusted-hazard ratio 8.05, 95% confidence intervals 3.77–15.8, p<0.0001). In
conclusion, NAFLD and its severity were strongly and independently associated with an
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increased risk of 1-year all-cause and cardiac re-hospitalization in elderly patients admitted
with acute HF.
Introduction
The prevalence of heart failure (HF) is high (10%) among persons aged 70 years or older and
its incidence is rapidly increasing, due to better life expectancy [1,2]. To date, although some
progress has been made in improving survival in hospitalized patients with acute HF, the rates
of hospital readmissions are rising dramatically, especially in the elderly [2,3]. High readmis-
sion rates not only drive burgeoning health care costs but also suggest that management of HF
is suboptimal [3]. Identifying novel predictors of hospital readmissions for HF in the elderly
would facilitate better discharge planning and, perhaps, decrease readmission rates.
Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that affects many organ
systems, including both the heart and the vasculature [4,5]. Growing evidence indicates that
patients with NAFLD have early changes in cardiac substrate metabolism, producing func-
tional, structural and arrhythmic consequences that are potentially linked to an increased risk
of new-onset HF [6]. For example, some population-based studies reported a strong associa-
tion between mildly elevated serum liver enzymes (a surrogate marker of NAFLD) and
increased long-term risk of new-onset HF [7–9]. Additionally, the Coronary Artery Risk
Development in Young Adults (CARDIA) Investigators recently found that computed tomog-
raphy-diagnosed NAFLD was independently associated with subclinical myocardial remodel-
ing and dysfunction, thus providing further insight into the potential link between NAFLD
and HF [10].
These findings support the view that NAFLD is implicated in HF development and might
be also a predictor of higher hospital readmissions for acute HF. We have previously explored
the association between NAFLD and the risk of all-cause hospital readmissions in a small sam-
ple of elderly patients admitted for acute HF [11]. However, the sample size was much lower
than that of the current study and no detailed information regarding the causes of hospital
readmissions as well as the severity of hepatic fibrosis in patients with NAFLD was available
[11].
Consequently, it remains currently uncertain whether NAFLD and its severity may inde-
pendently predict 1-year hospital re-admissions after HF. Thus, the aim of this study was to
examine whether ultrasound-diagnosed NAFLD and its severity–using the fibrosis (FIB)-4
score or other non-invasive markers of advanced NAFLD fibrosis–were associated with an
increased risk of 1-year all-cause and cardiac re-hospitalization in patients admitted initially to
the hospital with HF.
Materials and methods
Patients
We studied a cohort of patients consecutively admitted with a diagnosis of acute HF to the
Divisions of General Medicine or Geriatrics at the ‘Sacro Cuore’ Hospital of Negrar (Verona)
over the years 2013 and 2014 (n = 314). All patients were initially eligible for the study if they
had a confirmed clinical diagnosis of acute HF (pre-existing or de novo HF). In agreement
with the 2012 European Society of Cardiology guidelines [2], the clinical diagnosis of acute HF
was based on the presence of typical signs and symptoms of acute HF, increased NT pro-brain
natriuretic peptide (NT-proBNP) levels as well as radiographic findings of acute HF.
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From the initial eligible cohort, we excluded 102 (32.5%) patients with: 1) acute myocardial
infarction, end-stage kidney disease or malignancy (n = 11); 2) severe heart valve diseases or
prior heart valve surgery (n = 22); 3) decompensated cirrhosis or other known causes of
chronic liver diseases, including viral hepatitis and excessive alcohol consumption (defined as
>30 g/day for men and>20 g/day of alcohol intake for women, respectively) (n = 34); and 4)
those who died during the first hospital admission (in-hospital deaths; n = 35). As consequence
of this selection, 212 (67.5%) elderly patients hospitalized for acute HF were included in the
final analysis.
The local ethics committee/IRB of the ‘Sacro Cuore’ Hospital approved the study protocol,
and all participants gave their written informed consent.
Clinical and laboratory data
Body mass index (BMI) was measured as kilograms divided by the square of height in meters.
Blood pressure was measured with a standard mercury sphygmomanometer after patient had
been seated quietly for at least 5 min. Patients were considered to have hypertension if their
blood pressure was140/90 mmHg or if they were taking any anti-hypertensive drugs.
Serum levels of creatinine, liver enzymes (aspartate and alanine aminotransferases [AST
and ALT] and gamma-glutamyltransferase [GGT]), electrolytes, complete blood count and
other biochemical blood measurements were determined by standard laboratory procedures
in the central Laboratory of the hospital for all patients. Plasma NT-proBNP measurements
were determined using a chemiluminescent immunoassay method. Most patients had serum
liver enzyme levels within the reference ranges in our Laboratory, which for serum GGT levels
were 60 U/l for both sexes, and for aminotransferases were 10 to 40 U/l for women and 10 to
50 U/l for men, respectively. We also calculated the APRI index (AST to platelet ratio index),
the fibrosis (FIB)-4 score (that includes age, serum aminotransferases and platelet count in its
equation) and the NAFLD fibrosis score (that includes age, BMI, impaired fasting glycaemia/
diabetes status, serum aminotransferases, albumin and platelet count in its equation) in
patients with NAFLD as non-invasive markers of advanced hepatic fibrosis, using for the FIB-
4 and NAFLD fibrosis scores the new cutoffs proposed for patients with NAFLD aged65
years [12]. Glomerular filtration rate (eGFRCKD-EPI) was estimated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) study equation [13].
Presence of coronary heart disease (CHD) was defined as a documented history of myocar-
dial infarction, angina or coronary revascularization procedures. Chronic kidney disease
(CKD) was defined as the presence of eGFRCKD-EPI <60 ml/min/1.73 m
2; measurements of
albuminuria or proteinuria were not available. The diagnosis of persistent or permanent atrial
fibrillation was made on the basis of medical history (from reviewing hospital and physician
charts from all patients) and standard electrocardiograms. The presence of chronic obstructive
pulmonary disease (COPD) was confirmed by reviewing medical records of the hospital,
including diagnostic symptoms patterns, and results of lung function tests.
Hepatic ultrasonography and conventional echocardiography
At baseline, experienced radiologists (blinded to the patients’ clinical details) performed
hepatic ultrasonography for all patients. Hepatic steatosis was diagnosed based on characteris-
tic ultrasonographic features, such as diffuse hyperechogenicity of the liver relative to the kid-
neys, ultrasound beam attenuation and poor visualization of the intra-hepatic vessel borders
and diaphragm [14,15]. It is known that ultrasonography has a high sensitivity and specificity
for detecting moderate and severe hepatic steatosis. However, its sensitivity is reduced when
less than 20–30% of hepatocytes are steatotic [14].
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Conventional trans-thoracic echocardiography, which was performed by experienced car-
diologists (blinded to the patients’ clinical details), was used to measure left ventricular (LV)
diameters and wall thicknesses according to international standard criteria [16]. LV end-dia-
stolic and end-systolic volumes and ejection fraction at rest were measured at the apical
4-chamber and 2-chamber views (by modified Simpson rule) [16]. Echocardiographic mea-
surements were available in the majority of our patients (n = 196, 92.5%).
Statistical analyses
Data are presented as means±SD, medians and interquartile ranges or percentages. The pri-
mary outcome of the study was the first re-hospitalization at 1 year. Re-hospitalization data
were obtained from either reviewing the patients’ hospital records or contacting the patients’
physician and the referring cardiologist or contacting patients directly.
Differences in baseline clinical and biochemical characteristics between patients stratified
by 1-year re-hospitalization status at follow-up were tested with either the unpaired Student’s
t-test (for normally distributed variables) or the Kruskal-Wallis test for non-normally distrib-
uted variables (i.e., serum liver enzymes, triglycerides, FIB-4 score, eGFRCKD-EPI and NT-
proBNP). The χ2 test was used to test for between-group differences among the categorical
variables.
Univariate survival analysis was performed by the Kaplan-Meier analysis and the overall
significance was calculated by the log-rank test. Cox regression analysis was used to examine
the association between baseline NAFLD status and 1-year all-cause or cardiac re-hospitaliza-
tion rates after adjustment for potential confounding variables. The model assumptions for the
Cox proportional hazard regression models were checked by visual inspection of proportional
hazard assumption, Schoenfeld’s residuals and covariance matrix. Four forced-entry Cox
regression models were performed: an unadjusted model; a model adjusted for age, sex and
hospital ward (General Medicine vs. Geriatrics) (model 1); a model adjusted for age, sex, hospi-
tal ward, past history of HF, obesity (i.e., BMI30 kg/m2), diabetes, CHD, eGFRCKD-EPI,
plasma NT-proBNP levels and LV-ejection fraction (model 2); and, finally, a regression model
additionally adjusted for serum sodium and GGT concentrations (model 3). Covariates
included in these multivariable regression models were chosen as potential confounding fac-
tors on the basis of their significance in univariable analyses or on the basis of their biologic
plausibility. Results of Cox regression models were presented as hazard ratios (HR) and 95%
confidence intervals (CI). P values<0.05 were considered statistically significant.
Results
Overall, the patients included in the study had a mean age of 82±9 years, 59% had permanent/
persistent atrial fibrillation, 37.8% had established diabetes, 35.4% had CKD, 33.5% had pre-
existing CHD, 28% had a past history of HF, 18% had a LV-ejection fraction40%, and 51.4%
patients had NAFLD (defined as presence of fatty liver on ultrasonography among patients
with no history of excessive alcohol consumption or other known causes of chronic liver
disease).
In the whole cohort, the first all-cause re-hospitalizations at 1 year occurred in 99 (46.7%)
patients. Overall, 78% (n = 77) of these re-hospitalizations were due to worsening HF and 22%
to extra-cardiac causes (mainly due to respiratory and gastrointestinal diseases). The cumula-
tive re-hospitalization rates were 11.3% (n = 24) at 1 month, 25.5% (n = 54) at 3 months, 36.8%
(n = 78) at 6 months and 46.7% (n = 99) at 1 year.
Table 1 shows the baseline clinical and biochemical characteristics of patients stratified by
re-hospitalization status during the follow-up. At baseline, patients who had been hospitalized
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Table 1. Baseline clinical and biochemical characteristics of hospitalized patients with acute HF stratified by 1-year all-cause re-hospitalization
status at follow-up.
Without re-hospitalization (n = 113) With re-hospitalization (n = 99) p value
Male sex (%) 44.2 46.5 0.75
Age (years) 82 ± 10 82 ± 8 0.92
Body weight (kg) 77 ± 23 75 ± 19 0.40
Body mass index (kg/m2) 27.8 ± 6 26.8 ± 6 0.35
Heart rate (bpm) 85 ± 22 82 ± 20 0.31
Systolic blood pressure (mmHg) 132 ± 21 132 ± 23 0.87
Diastolic blood pressure (mmHg) 75 ± 12 76 ± 12 0.75
Pulse pressure (mmHg) 57 ± 17 56 ± 19 0.66
Sodium (mmol/l) 138 ± 6 136 ± 5 <0.05
Potassium (mmol/l) 4.2 ± 0.5 4.2 ± 0.5 0.83
Hemoglobin (g/dl) 12.2 ± 2 11.9 ± 2 0.26
White blood cell count (x 109/l) 8.03 ± 3 8.16 ± 3 0.76
Platelet count (x 109/l) 226 ± 73 222 ± 84 0.72
eGFRCKD-EPI (ml/min/1.73 m2) 55.1 ± 22 50.2 ± 22 0.09
GGT (U/l) 45 (24–81) 49 (24–96) <0.05
AST (U/l) 23 (18–31) 25 (19–33) 0.07
ALT (U/l) 18 (12–26) 20 (13–32) 0.15
AST/ALT ratio 1.44 ± 0.8 1.28 ± 0.6 0.08
NT-proBNP (pg/ml) 579 (312–1018) 761 (400–1456) <0.05
Total cholesterol (mmol/l) 3.72 ± 0.9 3.68 ± 0.9 0.81
Triglycerides (mmol/l) 0.99 (0.8–1.3) 0.98 (0.8–1.3) 0.74
LV-ejection fraction (%) 49.7 ± 14 46.2 ± 13 0.10
LV-ejection fraction40% (%) 14.9 23.2 0.14
Diabetes (%) 37.2 38.4 0.86
Chronic obstructive pulmonary disease (%) 15.9 20.2 0.42
CHD (%) 24.8 43.4 <0.005
Stroke (%) 4.4 7.1 0.42
Pacemaker or ICD (%) 15.9 26.3 0.07
Atrial fibrillation (%) 57.5 60.6 0.65
Chronic kidney disease (%) 38.0 33.3 0.53
ACE-inhibitors/ARB users (%) 59.8 51.5 0.23
Furosemide users (%) 98.2 98.0 0.85
Spironolactone users (%) 29.5 43.4 <0.05
Beta-blocker users (%) 60.7 70.7 0.14
Digoxin users (%) 11.6 11.1 0.91
Amiodarone users (%) 2.7 3.0 0.89
Antiplatelet drug users (%) 36.6 49.5 0.09
Oral anticoagulant users (%) 39.3 39.4 0.99
Statin users (%) 22.3 25.3 0.62
Hospital stay (days) 13.6 ± 7 13.1 ± 6 0.62
Geriatric ward (%) 47.0 34.3 0.07
NAFLD (%) 31.9 73.7 <0.0001
FIB-4 <2 (normal)* 60.0 47.9 <0.0001
FIB-4 2–2.67 (intermediate) 22.9 15.1
(Continued )
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during the follow-up were more likely to have pre-existing CHD and had higher plasma NT-
proBNP and GGT levels and lower serum sodium levels than those not requiring re-hospitali-
zation. Moreover, they were also more often treated with spironolactone, and tended to have
(insignificantly) lower values of LV-ejection fraction and eGFRCKD-EPI. Notably, the preva-
lence of NAFLD and its severity (using the FIB-4 score) were remarkably greater in patients
with re-hospitalization at follow-up than in those without.
At baseline, the two groups of patients did not significantly differ in terms of age, sex, BMI,
heart rate, blood pressure, complete blood count, plasma lipids, pre-existing diabetes and
other comorbid conditions (CKD, COPD and atrial fibrillation), nor in terms of the hospital
length of stay and current use of many ‘cardiovascular’ medications (including the use of lipid-
lowering drugs, ACE-inhibitors, angiotensin receptor blockers, beta-blockers, furosemide, dig-
italis, amiodarone, antiplatelet agents or anticoagulants).
S1 Table shows the clinical and biochemical data of the patients stratified by the hospital
ward. Patients admitted to the Geriatric ward were older and had a lower body weight and a
longer hospital stay than those admitted to the General Medicine ward. The two groups of
patients did not differ significantly in terms of most of other clinical and biochemical data,
except for a higher proportion of patients admitted to the General Medicine ward who were
treated with spironolactone or antiplatelet agents and who had established diabetes or
NAFLD.
When the whole sample of patients was stratified by NAFLD status at baseline, patients
with NAFLD (n = 109) were more likely to be male (56% vs. 34%), younger (80±9 vs. 84±9
years) and had higher BMI (28.4±7 vs. 25.8±5 kg/m2), higher serum triglycerides (1.19±0.5 vs.
0.95±0.4 mmol/l) and lower values of AST/ALT ratio and eGFRCKD-EPI compared to those
without NAFLD (n = 103). On the contrary, the two groups of patients did not differ signifi-
cantly in terms of most of the other clinical and biochemical data, including plasma NT-
proBNP levels and LV-ejection fraction (data not shown).
The cumulative proportions of patients with 1-year all-cause or cardiac re-hospitalization
by NAFLD status are shown in Fig 1 (panel A and B). The Kaplan-Meier analysis showed that
approximately 70% of patients with NAFLD at baseline were readmitted to the hospital at 1
year vs. only ~20% of those without NAFLD (p<0.0001 for the difference by the log-rank test).
Similar results were found for 1-year cardiac re-hospitalization (panel B).
As shown in Fig 2, the Kaplan-Meier curves for the rates of 1-year all-cause re-hospitaliza-
tion showed that the rate of this endpoint was higher in patients with ultrasound-diagnosed
NAFLD and high FIB-4 score (FIB-4 >2.67; a marker of advanced NAFLD fibrosis) as com-
pared to other subgroups of patients with normal or intermediate FIB4 scores or those without
NAFLD (p<0.0001 by the log-rank test). Almost identical results were found for 1-year cardiac
re-hospitalization (data not shown). Similar results were also observed when we used other
Table 1. (Continued)
Without re-hospitalization (n = 113) With re-hospitalization (n = 99) p value
FIB-4 >2.67 (high) 17.1 37.0
Sample size, n = 212. Data are expressed as means ± SD, medians (IQR) or relative proportions.
Note: Measurements of plasma NT-proBNP and LV-ejection fraction were available in 206 and 196 patients, respectively.
*The FIB-4 score was calculated only in patients with NAFLD.
Abbreviations: ARB, angiotensin receptor blocker; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHD, coronary heart disease;
eGFRCKD-EPI, estimated glomerular filtration rate (as estimated by the CKD-EPI equation); FIB-4, fibrosis-4 score; GGT, gamma-glutamyltransferase; LV,
left ventricular; NAFLD, nonalcoholic fatty liver disease; NT-proBNP, NT pro-brain natriuretic peptide.
https://doi.org/10.1371/journal.pone.0173398.t001
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non-invasive fibrosis scores to identify/exclude advanced NAFLD fibrosis, such as the APRI
index or the NAFLD fibrosis score (in this latter case, however, the number of patients with
available data for calculating the NAFLD fibrosis score was smaller due to the lack of extensive
measurement of serum albumin concentrations) (data not shown). However, these results
should be interpreted with some caution because all of these non-invasive fibrosis markers
have not been sufficiently validated in a non-NAFLD population.
Fig 1. Kaplan-Meier curves. Rates of 1-year all-cause (panel A) or cardiac (panel B) re-hospitalization in
hospitalized patients with acute HF stratified by their ultrasound-diagnosed NAFLD status at baseline.
Patients with NAFLD: closed circles; patients without NAFLD: open circles. P<0.0001 for the difference by the
log-rank test.
https://doi.org/10.1371/journal.pone.0173398.g001
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Table 2 shows the effect of adjustment for multiple potential confounders on the association
between NAFLD and the risk of 1-year all-cause or cardiac re-hospitalization. In univariable
regression analyses (unadjusted model), NAFLD was associated with an approximately
3.5-fold increased risk of all-cause re-hospitalization and with an approximately 5.9-fold
increased risk of cardiac re-hospitalization. After adjusting for age, sex and hospital ward
(model 1), NAFLD maintained a strong association with 1-year re-hospitalization. The
strength of this association was not attenuated after further adjustment for obesity, diabetes,
CHD, past history of HF, LV-ejection fraction, eGFRCKD-EPI and plasma NT-proBNP levels
Fig 2. Kaplan-Meier curves. Rates of 1-year all-cause re-hospitalization in hospitalized patients with acute
HF stratified by baseline NAFLD status and FIB-4 score The FIB-4 score was used to categorize the severity
of advanced liver fibrosis in patients with NAFLD. P<0.0001 for the difference by the log-rank test.
https://doi.org/10.1371/journal.pone.0173398.g002
Table 2. Cox regression analyses–Associations between NAFLD and risk of 1-year all-cause or car-
diac re-hospitalization rates in hospitalized patients with acute HF at baseline.
Cox Hazard Models Hazard ratio(s) 95% CI p value
All-cause re-hospitalization
NAFLD (yes vs. no)
Unadjusted model 3.50 2.23–5.49 <0.0001
Adjusted model 1 3.65 2.28–5.81 <0.0001
Adjusted model 2 4.60 2.69–7.94 <0.0001
Adjusted model 3 5.01 2.78–9.10 <0.0001
Cardiac re-hospitalization
Unadjusted model 5.86 3.27–10.4 <0.0001
Adjusted model 1 6.24 3.44–11.1 <0.0001
Adjusted model 2 8.76 5.30–16.4 <0.0001
Adjusted model 3 8.05 3.77–15.8 <0.0001
Sample size: n = 212 for 1-year all-cause re-hospitalizations and n = 187 for 1-year cardiac re-
hospitalizations, respectively. Data are expressed as hazard ratios ± 95% confidence intervals (CI) as
assessed by either univariable (unadjusted) or multivariable Cox hazard models.
Other covariates included in the three multivariable regression models, together with NAFLD, were as
follows: model 1: age, sex and hospital ward (General Medicine vs. Geriatrics); model 2: age, sex, hospital
ward, past history of HF, diabetes, CHD, obesity (i.e., BMI30 kg/m2), eGFRCKD-EPI, LV-ejection fraction
and plasma NT-proBNP; model 3: adjustment for the same variables included in model 2 plus serum sodium
and GGT levels.
https://doi.org/10.1371/journal.pone.0173398.t002
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(model 2). Finally, additional adjustment for circulating levels of sodium and GGT did not
appreciably weaken the association between NAFLD and risk of 1-year re-hospitalization
(model 3). Of note, in regression model 3 other independent predictors of increased 1-year all-
cause or cardiac re-hospitalization rates, together with NAFLD, were higher baseline levels of
plasma NT-proBNP and GGT.
Interestingly, NAFLD remained significantly associated with higher 1-year re-hospitaliza-
tion rates from all causes (model 3: adjusted-HR 7.02, 95% CI 3.6–13.5) and from cardiac
causes (model 3: adjusted-HR 13.1, 95% CI 5.2–31.6) even after excluding patients with re-hos-
pitalization in the early post-discharge period, i.e., re-hospitalizations at 1 month (n = 24).
Fig 3 shows the cumulative proportions of patients with all-cause re-hospitalization at 1
year after simultaneous stratification by ultrasound-diagnosed NAFLD status and serum GGT
levels (i.e., high GGT >46 U/l or normal GGT46 U/l; this cut-off corresponds to the median
value of serum GGT in the whole cohort of patients). The Kaplan-Meier analysis showed that
the risk of 1-year all-cause re-hospitalization was greatest in patients with NAFLD and high
GGT (approximately 75% of these patients were readmitted to the hospital at 1 year), interme-
diate in those with NAFLD alone (approximately 65% of these patients were readmitted to the
hospital at 1 year) and lowest in those without NAFLD, irrespective of their GGT levels. In
particular, the risk of 1-year re-hospitalization was similar for patients without NAFLD with
normal GGT and those with high GGT alone (approximately 25% of these patients were read-
mitted to the hospital at 1 year). Almost identical results were found for 1-year cardiac re-hos-
pitalization (data not shown).
We undertook other sensitivity analyses (subgroup analyses) to evaluate the robustness of
our findings. Notably, the association between NAFLD and 1-year all-cause re-hospitalization
was consistently demonstrated in all subgroups examined. In particular, we found that there
were significant age-adjusted associations between NAFLD and 1-year all-cause re-hospitaliza-
tion rates in both men (HR 3.12, 95% CI 1.5–6.7) and women (HR 4.16, 95% CI 2.3–7.7), in
those admitted to the hospital ward of General Medicine (HR 3.03, 95% CI 1.7–5.3) or Geriat-
rics (HR 4.5, 95% CI 2.1–10), in those with (HR 3.91, 95% CI 1.2–12.5) and without (HR 3.28,
95% CI 2.0–5.4) past history of HF, in those with (HR 3.23, 95% CI 1.5–7.1) and without (HR
3.70, 95% CI 2.1–6.7) pre-existing CHD, in those with (HR 8.33, 95% CI 2.6–25) and without
(HR 2.95, 95% CI 1.7–5.1) established diabetes, in those with (HR 4.33, 95% CI 2.1–8.5) and
Fig 3. Kaplan-Meier curves. Rates of 1-year all-cause re-hospitalization in hospitalized patients with acute
HF simultaneously stratified by baseline NAFLD status and serum gamma-glutamyltransferase (GGT)
concentrations (i.e., high or normal GGT according to its median value46 vs. >46 U/l). P<0.0001 for the
difference by the log-rank test.
https://doi.org/10.1371/journal.pone.0173398.g003
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without (HR 3.95, 95% CI 1.8–5.6) obesity, in those treated with (HR 3.71, 95% CI 1.8–7.7) or
without (HR 3.33, 95% CI 1.9–5.9) spironolactone, in those with higher (>1000 pg/ml: HR
5.26, 95% CI 2.6–10) or lower NT-proBNP (1000 pg/ml: HR 3.13, 95% CI 1.7–5.9), and in
those with LV-ejection fraction below 40% (40%: HR 7.15, 95% CI 2.1–24) or above 40%
(>40%: HR 3.23, 95% CI 2.0–5.3). Almost identical results were found for 1-year cardiac re-
hospitalization (data not shown).
Discussion
The novel results of this prospective study are as follows: 1) 1-year re-hospitalizations (most of
which were due to worsening HF) occurred in 46.7% of patients, who were discharged after
their first acute HF admission; 2) the prevalence of ultrasound-diagnosed NAFLD at baseline
was approximately 2.5-fold higher in patients with re-hospitalization at follow-up than in
those without; 3) patients with NAFLD had remarkably higher rates of 1-year all-cause and
cardiac re-hospitalization compared to their counterparts without NAFLD; both event rates
were particularly increased in NAFLD patients with advanced hepatic fibrosis (as estimated by
the FIB4 score or other non-invasive fibrosis scores); and 4) NAFLD and its severity were inde-
pendently associated with substantially increased rates of 1-year all-cause and cardiac re-hospi-
talization. Interestingly, these findings were consistent in all subgroups evaluated, including
also in those with and without established diabetes or prior CHD, in those with higher or
lower plasma NT-proBNP, and in those with preserved or reduced LV-ejection fraction at
baseline.
To our knowledge, this is the largest prospective study aimed at examining the prognostic
value of NAFLD per se in predicting 1-year all-cause and cardiac re-hospitalization rates in
elderly patients admitted for acute HF. Our results extend those that we recently reported in
a pilot study on a smaller sample of 107 elderly patients admitted for acute HF, in which
NAFLD was found to be significantly associated with higher 1-year all-cause re-hospitaliza-
tion rates [11]. All these 107 patients were included in the present study, but the sample size
was now almost doubled by including also patients admitted to the Geriatric ward of our
hospital over the same period of follow-up. Additionally, in the current study more detailed
information was also recorded regarding the severity of hepatic fibrosis in patients with
NAFLD (using the FIB-4 score and other non-invasive clinical markers of advanced NAFLD
fibrosis) as well as the cardiac and extra-cardiac causes of 1-year re-hospitalization for all
patients. From a statistical standpoint, the doubling of the sample size of the study (with a
consequent significant increase in the total number of clinical outcomes) allowed the
achievement of solid and reliable results both from the subgroup analyses and from the mul-
tivariable regression analyses after adjustment for established risk factors and potential
confounders.
Rates of 1-year re-hospitalization we observed in this study were comparable to those
reported by other investigators in large cohorts of hospitalized patients with acute HF with
similar baseline demographic characteristics [2,17–19]. In this study, we also found that higher
circulating levels of NT-proBNP and GGT were two independent predictors (along with
NAFLD) of higher 1-year all-cause and cardiac re-hospitalization rates. Previous studies
reported a strong and independent association between higher NT-proBNP and poor clinical
outcomes in patients with acute HF [20]. Similarly, previous studies also reported that the
presence of severe HF was frequently associated with increased serum GGT, bilirubin and ami-
notransferase levels [2,20]. Moreover, in a cohort of ambulatory patients with chronic HF,
increased serum GGT levels predicted independently the rates of mortality or heart transplan-
tation over a mean follow-up of 34 months [21].
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A possible caveat in interpreting the results of this study is that moderately elevated serum
liver enzyme levels may be present in patients with acute HF, possibly due to either the use of
some potentially hepato-toxic drugs (such as amiodarone or warfarin) or the coexistence of
congestive hepatopathy (i.e., a condition caused by passive venous congestion of the liver that
generally occurs in the setting of chronic cardiac conditions, such as chronic HF, constrictive
pericarditis, tricuspid regurgitation or right-sided HF of any cause) [2,22]. However, we
believe that the most important strength and the added value of our study was that the diagno-
sis of NAFLD was based on ultrasonography (and not on abnormal serum liver enzyme levels),
which is able to differentiate hepatic steatosis from congestive hepatopathy (mainly through
the ultrasonographic evaluation of both caval and supra-hepatic veins) [23]. We cannot, obvi-
ously, exclude that some of our patients with ultrasound-diagnosed NAFLD and raised serum
liver enzyme levels could also have a coexisting congestive hepatopathy. However, our patients
with hepatic steatosis (diagnosed by ultrasonography) exhibited the typical anthropometric
and biochemical features of NAFLD [24]. Furthermore, as shown in Fig 3, it is important to
underline that the highest risk of 1-year all-cause or cardiac re-hospitalizations was observed
in patients with hepatic steatosis and high serum GGT, intermediate in those with hepatic stea-
tosis alone, and the lowest in patients without hepatic steatosis, irrespective of their serum
GGT levels. In addition, there were no significant differences in baseline LV-ejection fraction
or use of potentially hepato-toxic drugs (such as warfarin and amiodarone) between those
with and those without re-hospitalization at follow-up. Finally, the significant association
between NAFLD and 1-year re-hospitalization persisted even after excluding those with re-
hospitalization in the early post-discharge period (i.e., patients with a higher likelihood of hav-
ing more ‘severe’ HF and possibly coexisting congestive hepatopathy).
A number of underlying mechanisms can explain the association between NAFLD and
increased 1-year re-hospitalization in patients with acute HF. Convincing evidence indicates
that NAFLD, especially in its more advanced forms [non-alcoholic steatohepatitis (NASH)
and advanced fibrosis], is not only associated with an increased risk of CHD, but is also
strongly associated with functional and structural cardiomyopathy that may lead to the devel-
opment of HF over time [4,6,10,25,26]. Moreover, NAFLD is also associated with enlarged left
atrial volume, and increased risk of atrial fibrillation (a known risk factor of new-onset HF)
[27–30]. Finally, clear evidence also indicates that NAFLD, especially NASH with varying
amounts of hepatic fibrosis, may exacerbate hepatic/peripheral insulin resistance and causes
the release of proinflammatory factors, vasoactive factors and thrombogenic molecules that
are important in the development of CHD and other functional, structural and arrhythmic
complications of the heart [4,6,25]. It is plausible to assume that one of the most important rea-
sons why patients with progressive NAFLD have recurrent HF over time could be largely due
to worsening CHD. This assumption may be also true in other different disease models in
which there is a high prevalence of hepatic steatosis, such as the chronic infections due to hepa-
titis C virus (HCV) or human immunodeficiency virus (HIV). Indeed, there is now accumulat-
ing evidence reinforcing the assertion that the presence of fatty/inflamed/fibrotic liver is a
shared important determinant for the development of CHD and other cardiac complications
in patients with HCV or HIV [31].
Our study has some limitations that should be mentioned. Firstly, this study is limited by its
single-center, observational design, which limits our ability to establish the causality of the
observed associations. Secondly, although our statistical models were extensive, unmeasured
confounding factors might partially explain the observed associations. Thirdly, the diagnosis
of NAFLD was based on ultrasonography and exclusion of secondary causes of chronic liver
disease but was not confirmed by liver biopsy, which is considered as the reference standard
for diagnosing and staging NAFLD [32]. However, we believe that it would have been
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hazardous to perform liver biopsies for these elderly HF patients with normal or only moder-
ately elevated serum liver enzymes. Indeed, ultrasonography enables a reliable and accurate
detection of moderate-to-severe hepatic steatosis compared with liver histology. A recent
meta-analysis reported that the overall sensitivity and specificity of ultrasonography for the
detection of moderate-to-severe fatty liver, compared to histology, were approximately 85%
and 95%, respectively [14]. Finally, the use of non-invasive markers of advanced NAFLD fibro-
sis (such the FIB-4, APRI or NAFLD fibrosis scores) has not been adequately validated in
patients with acute HF or in a general population. That said, future studies in larger cohorts of
well-characterized patients with NAFLD (as diagnosed by magnetic resonance-proton density
fat fraction and magnetic resonance elastography, which are rapidly being recognized as being
as good as liver biopsies) [33,34] are needed to better elucidate whether the severity of NAFLD
may differentially affect the risk of all-cause and cardiac re-hospitalization in patients admitted
for acute HF.
Despite these limitations, our study has important strengths, including its relatively large
sample size, the ultrasonographic diagnosis of NAFLD, the completeness of the dataset, the
ability to adjust for multiple clinical risk factors and potential confounding factors, and the
exclusion of patients with end-stage renal disease, cancer or cirrhosis.
In conclusion, our results show that NAFLD and its severity—using the FIB-4 score or
other non-invasive markers of advanced NAFLD fibrosis—were strongly and independently
associated with an increased risk of 1-year all-cause and cardiac re-hospitalization in elderly
patients admitted for acute HF. Further prospective studies are needed to corroborate these
findings in other independent samples.
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